Table 1

Patientcharacteristics and comparison of 2 cohorts of patients—HFrEF/HFmrEF versus those with HFpEF

Patient characteristicsTotal cohort (n=334)HFrEF/
HFmrEF (n=184)
HFpEF (n=150)P value
(HFrEF vs HFpEF)
Age72.5±11 years71±9 years74.5±110.001
Male:female57%:43%60%:40%47%:53%0.02
Ischaemic heart disease124/334 (37%)94/184 (51%)30/150 (20%)<0.001
Hypertension164/334 (49%)78/184 (42%)86/150 (57%)0.007
Diabetes mellitus137/334 (41%)72/184 (39%)65/150 (43%)0.43
Atrial fibrillation127/334 (38%)67/184 (36%)60/150 (40%)0.50
Valvular heart disease60/334 (18%)29/18431/1500.24
COPD/asthma/interstitial lung disease103/334 (31%)53/184 (29%)50/150 (33%)0.37
CKD177/334 (53%)81/184 (44%)96/150 (64%)<0.001
Cerebrovascular disease (CVA or previous TIA)43/334 (13%)22/184 (12%)21/150 (13%)0.6
Cancer23/334 (7%)15/184 (8%)8/150 (5%)0.3
Dementia27/334 (8%)16/184 (8%)11/150 (7%)0.5
Charlson Comorbidity Index7.6±2.17.4±27.9±2.20.03
Rockwood Frailty Score5.5±1.65.4 1.55.7±1.70.06
  • CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; CVA, cerebrovascular accident; HFmrEF, heart failure with mildly reduced ejection fraction; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; TIA, transient ischaemic attack.